Is Aurobindo Pharma share good to buy?

Is Aurobindo Pharma share good to buy?

Brokerage firm HDFC Securities has recommended to ‘buy’ Aurobindo Pharma’s stock with a potential upside of ~46%.

Why is Aurobindo Pharma stock falling?

Shares of Hyderabad-based drugmaker Aurobindo Pharma fell as much as 4.5 per cent to hit an intraday low of Rs 685.85 after it received a warning letter from the US drug regulator – US Food and Drug Administration (USFDA) for its Hyderabad-based Unit I, an active pharmaceutical ingredient (API) manufacturing facility.

What is the target of Aurobindo Pharma?

Emkay Global has buy call on Aurobindo Pharma Ltd. with a target price of Rs 850. The current market price of Aurobindo Pharma is Rs 633.55.

Will Auropharma go up?

Based on our forecasts, a long-term increase is expected, the “AUROPHARMA” stock price prognosis for 2027-05-07 is 888.422 INR. With a 5-year investment, the revenue is expected to be around +53.89%. Your current $100 investment may be up to $153.89 in 2027.

Why are Lupin shares falling?

Shares of Lupin dipped 6 per cent to Rs 816.25 in Monday’s intra-day trade, falling 9 per cent in the past two trading sessions after the drugmaker reported lower-than-expected margins and net profit in December quarter (Q3FY22) due to one-time expenses related to residual metformin returns and provision for aged stock …

Who is the owner of Aurobindo Pharma?

V. Ramprasad Reddy K. Nityananda Reddy
Aurobindo Pharma

Type Public
Founders V. Ramprasad Reddy K. Nityananda Reddy
Headquarters Hyderabad, Telangana, India
Products Pharmaceuticals generic drugs over-the-counter drugs vaccines diagnostics contact lenses animal health
Revenue ₹23,290 crore (US$3.1 billion) (2020)

Are Aurobindo drugs safe?

India’s Aurobindo Pharma has been one of the culprits found manufacturing the high blood pressure medicine valsartan with high levels of impurities that carry a risk of cancer. Now the FDA has savaged it in a warning letter for missteps that paved the pathway to the mess.

Is Aurobindo Pharma Debt Free?

In fiscal year 2021, Aurobindo Pharma Limited had -0.04 debt to equity ratio, which was a decrease from the previous financial year. The pharmaceutical company recorded a revenue of over 247.74 billion Indian rupees in financial year 2021.

Will ITC share price go up?

After tepid 12 per cent return in last one year, Edelweiss Wealth is highly bullish on ITC shares. The Edelweiss Wealth research says that there is strong possibility of trend reversal and the stock may go up to ₹450 apiece levels in long term. ITC share price today is ₹249.95 per share levels on NSE.

Is it good to invest in Lupin?

“Technically, the stock is very oversold. Long-term investors should start accumulating Lupin at current prices for the near-term targets of Rs 1083-1160. While Rs 960-883 will be excellent support levels,” AR Ramachandran, Co-founder & Trainer, Tips2Trades, told Financial Express Online.

Is Aurobindo a good company?

Aurobindo Pharma has an overall rating of 3.7 out of 5, based on over 378 reviews left anonymously by employees. 68% of employees would recommend working at Aurobindo Pharma to a friend and 62% have a positive outlook for the business.

When will the latest stock tips for Aurobindo Pharma Limited update?

Updated on 11th Feb 2022 Evening after Share Market – only valid for Intraday Shares & Stocks Trading Stock Tips for Aurobindo Pharma Limited. Plz. Note : Kindly check update date and time before making any position. Updated on 11th Feb 2022. Tips given here are free for learning purpose, You should not trade with this in Live Market.

What is the history of Aurobindo Pharma?

Aurobindo Pharma Ltd., incorporated in the year 1986, is a Large Cap company (having a market cap of Rs 25807.67 Crore) operating in Pharmaceuticals sector.

What are the key products/revenue segments of Aurobindo Pharma Ltd?

Aurobindo Pharma Ltd. key Products/Revenue Segments include Pharmaceuticals, Export Incentives, Scrap and Sale of services for the year ending 31-Mar-2021.